Anti-PD-1 drugs, including nivolumab, pembrolizumab, and cemiplimab, and anti-PD-L1 drugs, including atezolizumab and durvalumab, provided significant antitumor activity for lung cancer and improved the survival time of lung cancer patients (Figure 3). Here, CD274 is linked to lung carcinoma.